Allele |
Phenotype |
CCR5Δ32 |
Heterozygous variant delays disease progression while homozygous allele is strongly is associated with potent resistant to HIV infection [27]. |
Class I (B*27, 57, 58, A*03) |
B*27, 57, 58, A*03 positive individuals exhibit neuroprotective response with decreased impairment at baseline [25]. |
Class I HLA-B*07:02 |
B*07:02 positive individuals have accelerated disease progression when infected with B-clade HIV, but not when infected with C-clade HIV [28]. |
Bw4 HLA-B(B*44 & B*57) |
B*44-positive individuals homozygousfor Bw4 have a significantly lower set point viral load [29]. |
HLA Class I B-27 |
B-27 positive children exhibit delayed disease progression & protection from CNS impairment [26]. |
HLA Class I A-24 |
A-24 positive children exhibited rapid CNS disease progression with no impact on overall disease [26]. |
HLA Class I CW-2 |
CW-2 positive children exhibit delayed disease progression with no impact on CNS impairment [26]. |
HLA Class II DBQ 1-2 |
DBQ 1-2 positive children exhibit slower disease progression [26]. |
Alzheimer’s associated ApoE4 Class I HLA-DR*04 |
Synergistic action leads to greater neurocognitive decline in positive individuals [25]. |